Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFR
5. FFAI
6. TSLA
7. META
8. FICO
9. CART
10. LLY

Go back to Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 12c

Castle Biosciences Announces Third Quarter 2020 Results

November 9, 2020 4:05 PM EST

Q3 2020 revenues of $15.2 million, Q3 2020 YTD revenues of $45.4 million

DecisionDx-Melanoma report volume returned to quarterly year-over-year increase

Q3 2020 gross margin of 84%

Recently received final expanded positive Medicare coverage for DecisionDx-Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the third quarter and nine months ended Sept. 30, 2020.

The Castle team made significant progress on our strategic... More